Comparative Pharmacology
Head-to-head clinical analysis: AMMONIUM CHLORIDE 0 9 IN NORMAL SALINE versus FLOWTUSS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIUM CHLORIDE 0 9 IN NORMAL SALINE versus FLOWTUSS.
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE vs FLOWTUSS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonium chloride provides chloride ions to correct hypochloremic metabolic alkalosis and acts as a systemic acidifying agent. It is metabolized to urea and hydrochloric acid in the liver, thereby increasing hydrogen ion concentration in plasma and lowering pH.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.
Adults: 0.9% ammonium chloride in normal saline, intravenous infusion at a rate of 0.5-1 mL/kg/hour, typically 500-1000 mL over 4-8 hours, adjusted based on serum chloride and pH. Maximum infusion rate: 1 mL/kg/hour.
10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.
None Documented
None Documented
Variable; approximately 2-4 hours depending on renal function and acid-base status; prolonged in renal impairment.
Terminal elimination half-life is 4–6 hours in adults with normal renal function; prolonged to 8–12 hours in moderate renal impairment (CrCl 30–50 mL/min).
Renal: >95% as ammonium and chloride ions; minimal biliary/fecal elimination.
Renal elimination of unchanged drug accounts for 60–70%; hepatic metabolism (30–40%) with fecal excretion of metabolites via bile (20–25%) and urine (10–15%).
Category C
Category C
Expectorant/Systemic Acidifier
Expectorant